Opdivo is the first and only treatment to demonstrate superior efficacy in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy and resection ...

The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down ...

Checkmate, which is a personalized smart shopping tool aimed at making it easy for users to discover brands, apply savings and manage their orders post-purchase, said it secured $5 million in a seed ...

Other Participants in the Round Include Kevin Johnson (former CEO of Ebates at Rakuten), f7 Ventures, Blackbird Ventures, Scribble Ventures, Hyper and Susa Ventures SAN FRANCISCO--(BUSINESS ...

Thierry André and colleagues recently reported that nivolumab–ipilimumab provided an impressive absolute progression-free survival benefit at 36 months, which was 17% compared with nivolumab ...

This week, drug maker Bristol-Myers Squibb announced in a press release that the ongoing Phase 3 Checkmate-227 trial met its co-primary endpoint of progression-free survival with Opdivo plus Yervoy ...

Nivolumab failed to perform better than chemotherapy in patients with squamous as well as non-squamous non-small cell lung cancer (NSCLC). Bristol Myer Squibb (BMS)’s recent immunotherapy success, ...

Opdivo demonstrates superior overall survival in this Phase 3 trial (PRINCETON, NJ, January 11, 2015) – Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized Phase 3 ...

SAN FRANCISCO--(BUSINESS WIRE)--Checkmate, a personalized smart shopping tool that makes it easy for users to discover brands, apply savings and manage their orders post-purchase, today announced it ...